SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
BURLINGTON, Mass., April 07, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York, NY.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T : 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
